PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9225287-0	1997	RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	0-9	5-hydroxytryptamine receptor 2C	Rattus norvegicus	48-54	
20488736-7	2010	Intrathecal administration of the 5-HT2C receptor antagonist, 8-[5-2,4-dimethoxy-5-(4-trifluoromethylphenylsulphonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4,5]decane-2,4-dione (RS-102221: 30 mug) did not alter the mechanical threshold.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	180-189	5-hydroxytryptamine receptor 2C	Rattus norvegicus	34-40	
20488736-8	2010	Intrathecal pretreatment with RS-102221 (10 and 30 mug) reduced the antiallodynic effects of the highest dose of 5-HT2C agonists.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	30-39	5-hydroxytryptamine receptor 2C	Rattus norvegicus	113-119	
18339223-5	2008	Experiments1-4 revealed that systemic administration of the 5-HT2C antagonist RS 102221 (2 mg/kg) selectively decreases compulsive lever-pressing, whereas systemic administration of the 5-HT2A antagonist MDL11,939(0.2-5 mg/kg) or of the 5-HT2A/2C agonist DOI (0.05-5 mg/kg) did not have a selective effect on this behaviour.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	78-87	5-hydroxytryptamine receptor 2C	Rattus norvegicus	60-66	
9225287-4	1997	As part of an effort to further explore the function of 5-HT2C receptors, we have developed a selective 5-HT2C receptor antagonist, RS-102221 (a benzenesulfonamide of 8-[5-(5-amino-2,4-dimethoxyphenyl) 5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione).	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	132-141	5-hydroxytryptamine receptor 2C	Rattus norvegicus	56-62	
9225287-4	1997	As part of an effort to further explore the function of 5-HT2C receptors, we have developed a selective 5-HT2C receptor antagonist, RS-102221 (a benzenesulfonamide of 8-[5-(5-amino-2,4-dimethoxyphenyl) 5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione).	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	132-141	5-hydroxytryptamine receptor 2C	Rattus norvegicus	104-110	
9225287-4	1997	As part of an effort to further explore the function of 5-HT2C receptors, we have developed a selective 5-HT2C receptor antagonist, RS-102221 (a benzenesulfonamide of 8-[5-(5-amino-2,4-dimethoxyphenyl) 5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione).	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	167-253	5-hydroxytryptamine receptor 2C	Rattus norvegicus	104-110	
9225287-8	1997	Consistent with its action as a 5-HT2C receptor antagonist, daily dosing with RS-102221 (2 mg/kg intraperitoneal) increased food-intake and weight-gain in rats.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	78-87	5-hydroxytryptamine receptor 2C	Rattus norvegicus	32-38	
9225287-10	1997	It is concluded that RS-102221 is the first selective, high affinity 5-HT2C receptor antagonist to be described.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	21-30	5-hydroxytryptamine receptor 2C	Rattus norvegicus	69-75	
35092569-5	2022	Subsequent spinal administration of RS102221 to inhibit 5-HT2C receptors or SR57227 to activate 5-HT3 receptors reversed the analgesic effect of SAHA under both conditions.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	36-44	5-hydroxytryptamine receptor 2C	Rattus norvegicus	56-62	
34815296-6	2021	Intra-lOFC infusions of the 5-HT2C antagonist RS 102221 reduced risky choice in animals that showed a preference for the risky options of the rGT at baseline.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	46-55	5-hydroxytryptamine receptor 2C	Rattus norvegicus	28-34	
27511837-10	2016	Amongst the subtype selective 5HT2 antagonists, only RS 102221 (5HT2C-selectively) counteracted the rise in action potential firing elicited by 5HT.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	53-62	5-hydroxytryptamine receptor 2C	Rattus norvegicus	64-69	
31883927-6	2020	The reversal of somatic hyperalgesia and visceral hypersensitivity by VPA in FS rats was blocked by intrathecal administration of the selective 5-HT2C receptor antagonist RS-102221 (30 mug/10 muL) 30 min after each VPA injection.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	171-180	5-hydroxytryptamine receptor 2C	Rattus norvegicus	144-150